JP2011157403A5 - - Google Patents

Download PDF

Info

Publication number
JP2011157403A5
JP2011157403A5 JP2011116366A JP2011116366A JP2011157403A5 JP 2011157403 A5 JP2011157403 A5 JP 2011157403A5 JP 2011116366 A JP2011116366 A JP 2011116366A JP 2011116366 A JP2011116366 A JP 2011116366A JP 2011157403 A5 JP2011157403 A5 JP 2011157403A5
Authority
JP
Japan
Prior art keywords
antibody
antigen
binding fragment
day
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011116366A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011157403A (ja
JP5623335B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011157403A publication Critical patent/JP2011157403A/ja
Publication of JP2011157403A5 publication Critical patent/JP2011157403A5/ja
Application granted granted Critical
Publication of JP5623335B2 publication Critical patent/JP5623335B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2011116366A 1999-06-01 2011-05-24 Vla−1に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用 Expired - Lifetime JP5623335B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13703899P 1999-06-01 1999-06-01
US60/137,038 1999-06-01
US18533600P 2000-02-29 2000-02-29
US60/185,336 2000-02-29

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000620987A Division JP4817503B2 (ja) 1999-06-01 2000-06-01 Vla−1に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2012130177A Division JP2012176983A (ja) 1999-06-01 2012-06-07 Vla−1に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用
JP2014165702A Division JP5960762B2 (ja) 1999-06-01 2014-08-18 Vla−1に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用

Publications (3)

Publication Number Publication Date
JP2011157403A JP2011157403A (ja) 2011-08-18
JP2011157403A5 true JP2011157403A5 (enExample) 2012-07-26
JP5623335B2 JP5623335B2 (ja) 2014-11-12

Family

ID=26834850

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2000620987A Expired - Lifetime JP4817503B2 (ja) 1999-06-01 2000-06-01 Vla−1に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用
JP2007136041A Pending JP2007277253A (ja) 1999-06-01 2007-05-22 Vla−1に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用
JP2011116366A Expired - Lifetime JP5623335B2 (ja) 1999-06-01 2011-05-24 Vla−1に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用
JP2012130177A Pending JP2012176983A (ja) 1999-06-01 2012-06-07 Vla−1に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用
JP2014165702A Expired - Lifetime JP5960762B2 (ja) 1999-06-01 2014-08-18 Vla−1に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用
JP2016060029A Withdrawn JP2016121184A (ja) 1999-06-01 2016-03-24 Vla−1に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2000620987A Expired - Lifetime JP4817503B2 (ja) 1999-06-01 2000-06-01 Vla−1に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用
JP2007136041A Pending JP2007277253A (ja) 1999-06-01 2007-05-22 Vla−1に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2012130177A Pending JP2012176983A (ja) 1999-06-01 2012-06-07 Vla−1に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用
JP2014165702A Expired - Lifetime JP5960762B2 (ja) 1999-06-01 2014-08-18 Vla−1に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用
JP2016060029A Withdrawn JP2016121184A (ja) 1999-06-01 2016-03-24 Vla−1に対するブロッキングモノクローナル抗体および炎症性障害の処置のためのその使用

Country Status (28)

Country Link
US (5) US6955810B2 (enExample)
EP (3) EP1181054A1 (enExample)
JP (6) JP4817503B2 (enExample)
CN (1) CN1309419C (enExample)
AU (2) AU783989B2 (enExample)
BG (1) BG65579B1 (enExample)
BR (1) BR0011250A (enExample)
CA (1) CA2375827C (enExample)
CY (1) CY1116042T1 (enExample)
CZ (1) CZ300710B6 (enExample)
DK (2) DK1488806T3 (enExample)
EA (1) EA011384B1 (enExample)
EE (1) EE200100651A (enExample)
ES (2) ES2557768T3 (enExample)
GE (1) GEP20063774B (enExample)
HK (1) HK1043320A1 (enExample)
HU (1) HUP0202568A3 (enExample)
IL (2) IL146508A0 (enExample)
IS (1) IS6179A (enExample)
MX (1) MXPA01012388A (enExample)
NO (1) NO20015864L (enExample)
NZ (1) NZ515686A (enExample)
PT (2) PT1488806E (enExample)
SI (2) SI1488806T1 (enExample)
SK (1) SK17232001A3 (enExample)
TR (1) TR200103432T2 (enExample)
WO (1) WO2000072881A1 (enExample)
YU (1) YU85501A (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1181054A1 (en) * 1999-06-01 2002-02-27 Biogen, Inc. A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
EP1423431B1 (en) 2001-04-13 2010-06-16 Biogen Idec MA Inc. Antibodies to vla-1
AU2003215298A1 (en) * 2002-02-14 2003-09-04 Biogen, Inc. Alpha1beta1 antagonists for treatment of atherosclerosis
BR0315054A (pt) * 2002-11-01 2005-08-16 Boys Town Nat Res Hospital Ligando induzìvel para a integrina alfa 1 beta 1 e empregos
WO2005004800A2 (en) * 2003-06-20 2005-01-20 Morehouse School Of Medicine Trypanosome derived apoptotic factors (taf)
WO2005057755A1 (en) * 2003-12-09 2005-06-23 Electrotechnologies Selem, Inc. Polyphase claw-pole machines with a segmented magnetic circuit
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
WO2006133286A2 (en) * 2005-06-07 2006-12-14 Tel Hashomer Medical Research Infrastructure And Services Ltd. Treatment of tnf antagonist-resistant inflammatory disorders and related methods
CA2652815C (en) * 2006-05-25 2015-12-15 Biogen Idec Ma Inc. Methods of treating stroke
AU2009245724A1 (en) * 2008-05-09 2009-11-12 Ablynx N.V. Amino acid sequences directed against integrins and uses thereof
CN102946904A (zh) * 2010-06-18 2013-02-27 埃克斯生物科技公司 关节炎治疗
CA2824089A1 (en) * 2011-02-03 2012-08-09 Santarus, Inc. Selection and treatment of subjects
WO2013123114A2 (en) 2012-02-16 2013-08-22 Santarus, Inc. Antibody formulations
WO2019018688A1 (en) * 2017-07-20 2019-01-24 The University Of Virginia Patent Foundation METHODS OF TREATING OR PREVENTING A NEUROLOGICAL DISORDER OF THE IMMUNE SYSTEM

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP3101690B2 (ja) * 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AU7247191A (en) * 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) * 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) * 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5391481A (en) * 1990-08-31 1995-02-21 The Trustees Of Columbia University Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof
US5871907A (en) * 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
CA2127462C (en) 1992-01-13 1999-03-23 Roy R. Lobb Treatment for asthma
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6307026B1 (en) * 1992-12-10 2001-10-23 Celltech Limited Humanized antibodies directed against A33 antigen
SG44845A1 (en) 1993-01-12 1997-12-19 Biogen Inc Recombitant anti-vla4 antibody molecules
WO1994017828A2 (en) 1993-02-09 1994-08-18 Biogen, Inc. Treatment for insulin dependent diabetes
US6111598A (en) * 1993-11-12 2000-08-29 Peveo, Inc. System and method for producing and displaying spectrally-multiplexed images of three-dimensional imagery for use in flicker-free stereoscopic viewing thereof
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
DE69535133T2 (de) 1994-01-25 2008-08-21 Elan Pharmaceuticals, Inc., San Francisco Humanisierte antikörper gegen das leukozytenadhäsionsmolekül vla-4
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
ATE195428T1 (de) * 1994-04-26 2000-09-15 Kanebo Ltd Arznei für rheumatoide arthritis
JPH08131185A (ja) * 1994-11-14 1996-05-28 Sumitomo Electric Ind Ltd マウスvla−1分子に対するモノクローナル抗体
JPH08160972A (ja) 1994-12-01 1996-06-21 Sega Enterp Ltd エフェクト制御方法、制御装置およびこれを利用したカラオケ装置
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9516399D0 (en) 1995-08-10 1995-10-11 Camelot Superabsorbents Ltd Process for the production of water-absorbing compositions
EP0859841B1 (en) * 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
EP0773288A3 (en) 1995-08-29 1997-07-09 Kirin Brewery Chimera animal and its method of manufacture
DE19534177A1 (de) * 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
GB9519667D0 (en) 1995-09-27 1995-11-29 Univ Manchester Pharmaceutical composition
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
FR2745912B1 (fr) * 1996-03-08 1998-05-29 Lorraine Laminage Procede et dispositif de controle de la soudabilite de toles sandwich
US6127524A (en) * 1996-10-18 2000-10-03 Dade Behring Inc. Binding molecules and computer-based methods of increasing the binding affinity thereof
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
ATE230277T1 (de) 1997-06-13 2003-01-15 Genentech Inc Stabilisierte antikörperformulierung
ES2285841T3 (es) 1998-05-22 2007-11-16 Boys Town National Research Hospital Uso de inhibidores del receptor de integrina alfa1beta1 e inhibidores de tgf-beta1 en el tratamiento de la enfermedad renal.
DE19831710A1 (de) * 1998-07-15 2000-01-20 Merck Patent Gmbh Diacylhydrazinderivate
AU751157B2 (en) 1998-10-06 2002-08-08 Biogen Idec Ma Inc. Crystals of the alpha 1 beta 1 integrin I-domain and their use
ES2243259T3 (es) * 1999-04-22 2005-12-01 Biogen Idec Ma Inc. Metodo para tratar la fibrosis utilizando un antagonista de la subunidad alfa 4 de la integrina.
EP1181054A1 (en) 1999-06-01 2002-02-27 Biogen, Inc. A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders
EP1408839A1 (de) 1999-06-17 2004-04-21 Kai Dr. Desinger Chirurgische sonde zur minimal invasiven gewebeentnahme
AU4259901A (en) 2000-03-28 2001-10-08 Cambridge University Technical Services Limited Receptor/peptide crystal structure for identification of inhibitors
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
DE10028402A1 (de) 2000-06-13 2001-12-20 Merck Patent Gmbh Pyridin-2-yl-aminoalkycarbonylglycyl-beta-alanin und Derivate
US7153944B2 (en) 2000-07-31 2006-12-26 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
EP1423431B1 (en) * 2001-04-13 2010-06-16 Biogen Idec MA Inc. Antibodies to vla-1
AU2003215298A1 (en) 2002-02-14 2003-09-04 Biogen, Inc. Alpha1beta1 antagonists for treatment of atherosclerosis
KR101115797B1 (ko) 2002-08-01 2012-07-27 이뮤노메딕스, 인코오포레이티드 알파 태아 단백질 Immu31 항체 및 융합단백질, 및이들의 이용 방법
US20040208870A1 (en) 2003-01-30 2004-10-21 Medimmune, Inc. Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
WO2005019177A1 (en) 2003-08-14 2005-03-03 Icos Corporation Aminopiperidine amide derivatives as vla-1 integrin antagonists and uses thereof
WO2005019200A2 (en) 2003-08-14 2005-03-03 Icos Corporation Aryl piperidine derivatives as vla-1 integrin antagonists and uses thereof
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
WO2006133286A2 (en) 2005-06-07 2006-12-14 Tel Hashomer Medical Research Infrastructure And Services Ltd. Treatment of tnf antagonist-resistant inflammatory disorders and related methods
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US20080118496A1 (en) 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
CA2652815C (en) 2006-05-25 2015-12-15 Biogen Idec Ma Inc. Methods of treating stroke
JP4951596B2 (ja) 2008-07-31 2012-06-13 株式会社日立製作所 冷却システム及び電子装置
PE20120359A1 (es) 2009-03-06 2012-04-13 Genentech Inc Formulacion con anticuerpo
CN107095846A (zh) 2009-12-21 2017-08-29 霍夫曼-拉罗奇有限公司 抗体配制剂
CA2824089A1 (en) 2011-02-03 2012-08-09 Santarus, Inc. Selection and treatment of subjects
US9018035B2 (en) 2012-01-11 2015-04-28 Panasonic Intellectual Property Management Co., Ltd. Pressed-contact type semiconductor device and method for manufacturing the same
WO2013123114A2 (en) 2012-02-16 2013-08-22 Santarus, Inc. Antibody formulations

Similar Documents

Publication Publication Date Title
JP2022031635A5 (enExample)
JP2013198490A5 (enExample)
JP2014526898A5 (enExample)
JP2012121878A5 (enExample)
JP2010526028A5 (enExample)
HRP20250807T1 (hr) Protutijela koja vežu ljudski cgrp receptor
JP2014110800A5 (enExample)
JP2010536384A5 (enExample)
JP2012070737A5 (enExample)
RU2017128882A (ru) Антитела к биотину и способы их применения
RU2571204C3 (ru) Специфические связывающие агенты против в7-н1
JP2014205674A5 (enExample)
RU2018112861A (ru) Стабильные антитела, связывающиеся с несколькими антигенами
JP2009225799A5 (enExample)
AU2016204274A1 (en) Antibodies that bind to OX40 and their uses
JP2021514973A5 (enExample)
JP2014519334A5 (enExample)
HRP20190008T4 (hr) Prevencija i liječenje sinukleinopatske i amiloidogene bolesti
RU2016100892A (ru) Антитела против tweakr и их применение
NZ602040A (en) Anti-lrp6 antibodies
JP2014502955A5 (enExample)
JP2013538057A5 (enExample)
JP2014511179A5 (enExample)
JP2010500371A5 (enExample)
JP2017052784A5 (enExample)